• IGBA Releases Trade Principles to Foster Trade in Generic and Biosimilar Medicines

    GENEVA – 26 June 2019 – The International Generic and Biosimilar medicines Association (IGBA) today released a revised report Trade Principles: Generic and Biosimilar Medicines which addresses how trade agreements can be designed to foster trade in generic and biosimilar medicines and Read More
  • Committing to Global Health: Balancing Access and Sustainability key to success

    Warsaw, Poland, 13 June 2019 - Generic, biosimilar and value added medicine manufacturers deliver increased access to medicines worldwide. This access could be threatened by shortsighted cost-containment policies that make manufacturing and supply unsustainable. Focused pharmaceutical policies based on healthy competition, Read More
  • Contribution of the generic and biosimilar medicines industries to the 2030 United Nations Agenda for Sustainable Development - Universal Health Coverage

    Geneva, 20 May 2019 - Generic and biosimilar medicines have improved the quality of life of patients all over the world by increasing access to high-quality medicines. It is useful to report data that shows the actual impact of generic and Read More
  • IGBA congratulates health Canada for decision on biologics naming that supports growing global consensus

    Geneva, 27 February 2019 - The International Generic and Biosimilar medicines Association (IGBA) welcomes Health Canada’s decision to proceed with a biologic naming policy that identifies all biologic medicines, including biosimilars, by their unique brand name and non-proprietary (common) name, without Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site